Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CYCCP - Cyclacel Pharmaceuticals, Inc.
Market Cap 31.18M P/E - EPS this Y - Ern Qtrly Grth -
Income -22.76M Forward P/E - EPS next Y - 50D Avg Chg 31.00%
Sales 420k PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 20.27 EPS next 5Y - 52W High Chg -27.00%
Recommedations - Quick Ratio 0.77 Shares Outstanding 12.50M 52W Low Chg 171.00%
Insider Own 0.48% ROA -86.33% Shares Float 1.14M Beta 0.57
Inst Own 0.06% ROE -272.63% Shares Shorted/Prior 56/56 Price 16.40
Gross Margin 100.00% Profit Margin - Avg. Volume 2,224 Target Price -
Oper. Margin -17,290.32% Earnings Date May 9 Volume 282 Change 2.56%
Healthcare | Biotechnology | United States
About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Cyclacel Pharmaceuticals, Inc. News
04/30/24 Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
04/25/24 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
08:15 AM Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
03/20/24 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
03/19/24 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/13/24 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
03/07/24 Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/06/24 Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
02/20/24 Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
01/30/24 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
01/08/24 Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
01/02/24 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
12/22/23 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
12/18/23 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
12/12/23 Cyclacel Pharmaceuticals Announces Reverse Stock Split
11/30/23 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
11/28/23 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
11/14/23 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
11/13/23 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
11/07/23 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
CYCCP Chatroom

User Image tradingtwenty Posted - 04/30/24

$CYCCP $CYCC has trended 57 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 30, 2024 07:00 AM: Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules Link: https://tradingtwenty.com/news/450011/cyclacel-pharmaceuticals-announces-80-million-private-placement-priced-at-the-market-under-nasdaq-rules

User Image EpiCRise98 Posted - 04/30/24

$CYCC $CYCCP

User Image Stock_Titan Posted - 04/30/24

$CYCC $CYCCP Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-announces-8-0-million-private-placement-sr9c8yqxkqjn.html

User Image HaltTradeAlert Posted - 04/24/24

$CYCCP Halt Time: 14:01:40 Issue Symbol: CYCCP Reason Code: LUDP Last Price: $9.11 Market Cap: $0 Volume: 12849.0 Relative Volume: 5.32 Shares Float: 0 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

User Image HaltTradeAlert Posted - 04/24/24

$CYCCP Halt Time: 13:16:50 Issue Symbol: CYCCP Reason Code: LUDP Last Price: $10.77 Market Cap: $0 Volume: 12547.0 Relative Volume: 5.26 Shares Float: 0 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

User Image HaltTradeAlert Posted - 04/10/24

$CYCCP Halt Time: 13:43:43 Issue Symbol: CYCCP Reason Code: LUDP Stock Price: $17.30 Market Cap: 32.895M Volume: 1,909 Relative Volume: 1.62 Shares Float: 1.15M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image Stock_Titan Posted - 1 month ago

$CYCC $CYCCP Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-to-present-new-clinical-data-at-2024-asco-ghg88cbij46t.html

User Image Stock_Titan Posted - 03/19/24

$CYCC $CYCCP Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-wtdhhfamexws.html

User Image Stock_Titan Posted - 03/13/24

$CYCC $CYCCP Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-cw03dgo1u91t.html

User Image HaltTradeAlert Posted - 03/07/24

$CYCCP Halt Time: 15:58:47 Issue Symbol: CYCCP Reason Code: LUDP Stock Price: $19.80 Market Cap: 37.649M Volume: 1,427 Relative Volume: 0.97 Shares Float: 740.56k Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image Stock_Titan Posted - 03/07/24

$CYCC $CYCCP Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-announces-preclinical-proof-of-concept-data-npu7k4r1eun7.html

User Image Stock_Titan Posted - 03/06/24

$CYCC $CYCCP Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-announces-receipt-of-2-9-million-r-d-tax-8csrd5co4z8j.html

User Image Stock_Titan Posted - 02/20/24

$CYCC $CYCCP Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-to-participate-in-2024-bio-ceo-investor-zu8a2xq4mne4.html

User Image tickeron Posted - 01/17/24

$NBIX $ALKS $CYCCP Biopharmaceutical Surge: $NBIX, $ALKS, $CYCCP, $ZBH Drive Remarkable +14.87% Performance Boost in Plastic Surgery Sector. . https://srnk.us/go/4971651

User Image BigWins3 Posted - 01/12/24

@Turbo4365 Preferred, $CYCCP

User Image Stock_Titan Posted - 01/08/24

$CYCC $CYCCP Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-s5mlv1wxvd8d.html

User Image Stock_Titan Posted - 01/02/24

$CYCC $CYCCP Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-to-present-at-biotech-showcase-1y7i6ohd7kmn.html

User Image tradeXLNC Posted - 12/29/23

Keep $CYCC on watch - trading at $2.90s warrants $CYCCP are trading at 16.95, RS/low floats have been the theme this whole month- this can get hot above $3.14 res zone. $SNTG halted just now. These names hitting radar all day.

User Image Stock_Titan Posted - 12/22/23

$CYCC $CYCCP Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-announces-registered-direct-and-private-bu1s3wogwisc.html

User Image magnoliaspx58 Posted - 12/18/23

$CYCC $CYCCP

User Image Stock_Titan Posted - 12/18/23

$CYCC $CYCCP Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-reports-fadraciclib-phase-1-data-suggesting-auyfpib46ljv.html

User Image tickeron Posted - 12/10/23

$NBIX $ACAD $ALKS Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly Gain📈. The installation industry, particularly in the residential segment, has seen a remarkable surge in stock performance over the past month..... https://srnk.us/go/4938103

User Image stockilluminati Posted - 11/30/23

$CYCCP https://www.stockilluminati.com/cyccp/news.php - Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

User Image stockilluminati Posted - 11/28/23

$CYCCP https://www.stockilluminati.com/cyccp/news.php - Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

User Image Stock_Titan Posted - 11/28/23

$CYCC $CYCCP Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q https://www.stocktitan.net/news/CYCC/cyclacel-receives-notification-of-deficiency-from-nasdaq-regarding-eodj16m8ed8s.html

User Image Stock_Titan Posted - 11/13/23

$CYCC $CYCCP Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-reports-third-quarter-financial-results-and-h9fqrd9vsmlp.html

User Image Stock_Titan Posted - 11/07/23

$CYCC $CYCCP Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-to-release-third-quarter-2023-financial-xz5oaafhl0s9.html

User Image stockilluminati Posted - 08/09/23

$CYCCP https://www.stockilluminati.com/cyccp/earnings.php - Experience the power of predictive analytics with our Earnings Call Sentiment Analysis There were 21 positive comments, 3 negative comments and 149 neutral comments

User Image stockilluminati Posted - 08/09/23

$CYCCP https://www.stockilluminati.com/cyccp/news.php - Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Call Transcript

User Image Stock_Titan Posted - 08/09/23

$CYCC $CYCCP Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update https://www.stocktitan.net/news/CYCC/cyclacel-pharmaceuticals-reports-second-quarter-financial-results-rrjnq5br98pw.html